<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02695368</url>
  </required_header>
  <id_info>
    <org_study_id>EPOS</org_study_id>
    <nct_id>NCT02695368</nct_id>
  </id_info>
  <brief_title>The Effect of Plasma-air-filtration on the Incidence of Surgical Site Infections in Orthopaedic Surgery</brief_title>
  <acronym>EPOS</acronym>
  <official_title>The Effect of Air-filtration Through a Plasma Chamber on the Incidence of Surgical Site Infections in Orthopaedic Surgery: a Double-blind, Randomized, Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Swedish Research Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Karolinska Institutet</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a multicenter, double-blind, randomized, controlled trial conducted at six major
      university and teaching hospitals with a catchment population of approximately 2 million. In
      the current study it has been hypothesized that a non-invasive air cleaner utilizing a plasma
      chamber can significantly reduce the incidence of surgical site infections (SSIs).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite operating in clean theaters, surface sterilization, and antibiotics, surgical site
      infections (SSI) after orthopaedic surgery have an estimated incidence of 1-4%. This feared
      complication is associated with long-term antibiotics, repeated surgeries, prolonged hospital
      stays, economic burden and a poorer end result for individual patients. It is therefore of
      great importance to prevent SSI.While skin bacteria and contaminated surfaces have generally
      been claimed to be the main cause of infections, there are estimates that approximately 20%
      of hospital-acquired infections are air-transmitted, making this an interesting intervention
      target. Novaerus is an air-cleaner that sterilizes the air particles through a plasma
      chamber. Air in the operating theatre is pumped through the chamber (80-380 m3/Hr) and by
      using a small current it transforms the gas in the vicinity of the electrode into plasmaand
      eradicates any bacteria that pass through.The small size of the machine allows it to fit into
      any operating theater without interfering with existing equipment. This technology can reduce
      the number of colony forming units (CFU) when in hospital settings. In non-randomized
      settings it has been correlated to reduced respiratory infections, reduced personnel
      sick-leave, and absence of severe infectious outbreaks. Its effect has not been validated in
      randomized controlled trials. Both local and national registry data will be used according to
      availability.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 10, 2017</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with surgical site infection after orthopaedic surgery, defined as any of the following: using antibiotics targeting Staphylococcus aureus, having ICD-codes or surgery codes indicating postoperative infection.</measure>
    <time_frame>Within 12 weeks after surgery</time_frame>
    <description>All definitions are merged into one binary outcome measure as &quot;any(No. &gt; 0)&quot;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patients using any antibiotics after surgery</measure>
    <time_frame>Two treatment days or more during the first 30 postoperative days</time_frame>
    <description>This is identified either via hospital information system or from the national drug registry. Usage is defined as withdrawal or prescription of a drug with ATC code within the J01 group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days with antibiotics</measure>
    <time_frame>During the first 30 postoperative days</time_frame>
    <description>This is identified either via hospital information system or from the national drug registry. Usage is defined as withdrawal or prescription of a drug with ATC code within the J01 group. Number of days is deduced from the prescribed dosage or if not present the average daily dosage for that particular drug is used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients using any antibiotics after surgery</measure>
    <time_frame>Two treatment days or more during the first 90 postoperative days</time_frame>
    <description>This is identified either via hospital information system or from the national drug registry. Usage is defined as withdrawal or prescription of a drug with ATC code within the J01 group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days with antibiotics</measure>
    <time_frame>Two treatment days or more during the first 90 postoperative days</time_frame>
    <description>This is identified either via hospital information system or from the national drug registry. Usage is defined as withdrawal or prescription of a drug with ATC code within the J01 group. Number of days is deduced from the prescribed dosage or if not present the average daily dosage for that particular drug is used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>during the first 2 postoperative years</time_frame>
    <description>Any cause of death</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">19000</enrollment>
  <condition>Orthopaedic Surgery (30 Minutes or Longer)</condition>
  <arm_group>
    <arm_group_label>Exposed patients: Plasma-filter on</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Those operated with Novaerus NV800 on for at least 2 Days prior to index surgery. This Group will also in the analysis be sub-grouped according to measurements prior to study start into:
regular operating theater
ultra-Clean operating theaters</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Unexposed patients: Plasma-filter off</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Those with Novaerus NV800 off for at least 2 Days prior to index surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mixed patients: Plasma-filter on or off</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Those receiving multiple surgeries in different theaters with Novaerus NV800 on or off status will belong to a mixed Group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Novaerus NV800 on</intervention_name>
    <description>The air-cleaner sterilizes the air particles through a plasma chamber. Air in the operating theatre is pumped through the chamber (80 - 380 m3/Hr) and by using a small current it transforms the gas in the vicinity of the electrode into plasma and eradicates any bacteria that pass through. The air-cleaner has to have been turned on for at least 2 days prior to the surgical intervention.</description>
    <arm_group_label>Exposed patients: Plasma-filter on</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Novaerus NV800 off</intervention_name>
    <description>The machine decribed above is running but the plasma filter chamber isn't active, i.e. the placebo group.</description>
    <arm_group_label>Unexposed patients: Plasma-filter off</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Novaerus NV800 on or off</intervention_name>
    <description>Patients with multiple surgeries that have been operated during both periods when the apparatus has been on and off will belong to this mixed group.</description>
    <arm_group_label>Mixed patients: Plasma-filter on or off</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients that undergo a 30 minute or longer orthopaedic surgery

        Exclusion Criteria:

          -  The following surgeries will be excluded: already infected surgical site, defined as:
             ICD-codes indicating infection, Open fractures, Traumatic wounds, Vacuum assisted
             wound therapy

          -  Patients that have had antibiotics prescribed 2 weeks or less prior to surgery

          -  Patients that have actively marked their hospital charts with an added privacy notice
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Max Gordon, M.D, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Danderyd Hospital, Stockholm, Sweden</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Max Gordon, M.D., PhD</last_name>
    <phone>+46 8 123 558 84</phone>
    <email>max.gordon@ki.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anders Persson, MD</last_name>
    <phone>+46 8 123 580 76</phone>
    <email>anders.persson@sll.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Danderyds Sjukhus AB</name>
      <address>
        <city>Stockholm</city>
        <zip>182 88</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anders Persson, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Olof Sk√∂ldenberg, MD, PhD</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2016</study_first_submitted>
  <study_first_submitted_qc>February 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 1, 2016</study_first_posted>
  <last_update_submitted>January 23, 2018</last_update_submitted>
  <last_update_submitted_qc>January 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska Institutet</investigator_affiliation>
    <investigator_full_name>Max Gordon</investigator_full_name>
    <investigator_title>M.D., PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Surgical Wound Infection</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

